BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) — Market Cap & Net Worth
Market Cap & Net Worth: BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) has a market capitalization of $671.48 Million ($671.48 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11054 globally and #2710 in its home market, demonstrating a -6.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BridgeBio Oncology Therapeutics, Inc.'s stock price $8.39 by its total outstanding shares 80032823 (80.03 Million). Analyse BBOT cash generation efficiency to see how efficiently the company converts income to cash.
BridgeBio Oncology Therapeutics, Inc. Market Cap History: 2025 to 2026
BridgeBio Oncology Therapeutics, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $1.00 Billion to $671.48 Million (0.00% CAGR).
BridgeBio Oncology Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BridgeBio Oncology Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BBOT by Market Capitalization
Companies near BridgeBio Oncology Therapeutics, Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to BridgeBio Oncology Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
BridgeBio Oncology Therapeutics, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, BridgeBio Oncology Therapeutics, Inc.'s market cap moved from $1.00 Billion to $ 671.48 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $671.48 Million | -32.99% |
| 2025 | $1.00 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of BridgeBio Oncology Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $671.48 Million USD |
| MoneyControl | $671.48 Million USD |
| MarketWatch | $671.48 Million USD |
| marketcap.company | $671.48 Million USD |
| Reuters | $671.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients… Read more